The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Consortium, 2012Parkinson’s Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
Objective/Rationale:
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role... -
MJFF Research Grant, 2009The Validation of Anxiety Scales in Parkinson's Disease
Objective/Rationale:
This study has two objectives:
1. To assess the occurrence and symptoms of anxiety disorders in Parkinson's disease, including atypical anxiety syndromes, and anxiety states... -
Rapid Response Innovation Awards, 2009The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets... -
Research Grant, 2022Development And Validation Of A Miro1 Biomarker Assay Using White Blood Cells
Study Rationale: The mitochondrial protein Miro1 fails to be degraded and this defect impairs mitophagy in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms...
-
Aligning Science Across Parkinson's, 2021Understanding and Manipulating Cellular and Circuit-level Vulnerability to Neurodegeneration in Parkinson’s Disease
Study Rationale:
Many people with Parkinson’s disease develop untreatable cognitive symptoms, including problems with attention, decision-making, and dementia at late stages of the disease, due to... -
Therapeutic Pipeline Program, 2013Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease
Objective/Rationale:
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.